Sandu Pharmaceuticals September revenue rises to Rs 19.43 crore

Sandu Pharmaceuticals Limited reported standalone revenue from operations of Rs 19.43 crore for the three months ended September 30, 2026, up from Rs 16.39 crore in the preceding June quarter. Total income was Rs 19.47 crore and profit before exceptional items and tax was Rs 85.91 lakh in the September quarter.

What did Sandu Pharmaceuticals report for the September 2026 quarter?

Sandu Pharmaceuticals reported revenue from operations of Rs 19.43 crore for the three months ended September 30, 2026. Other income was Rs 3.71 lakh, taking total income to Rs 19.47 crore. The figures are standalone and unaudited, and the board approved them at its meeting on November 14, 2026.

Total expenses were Rs 18.61 crore in the September 2026 quarter, compared with total income of Rs 19.47 crore. This resulted in profit before exceptional items and tax of Rs 85.91 lakh. The filing reported basic earnings per equity share of Rs 0.81 for the quarter, with each equity share carrying a face value of Rs 10.

The September-quarter statement was prepared under Indian Accounting Standards, referred to as Ind AS in the filing. Sandu Pharmaceuticals said its Audit Committee reviewed the results before the board took them on record on November 14, 2026. Dave & Dave Chartered Accountants, Mumbai, issued the limited review report referred to in the announcement.

How did Sandu Pharmaceuticals compare with the June 2026 quarter?

Sandu Pharmaceuticals increased revenue from operations by Rs 3.04 crore from Rs 16.39 crore in the three months ended June 30, 2026 to Rs 19.43 crore in the September quarter. Other income also increased, moving from Rs 1.74 lakh in June to Rs 3.71 lakh in September. Consequently, total income rose by Rs 3.06 crore, from Rs 16.41 crore to Rs 19.47 crore.

Profit before exceptional items and tax rose by Rs 49.86 lakh over the same period, from Rs 36.05 lakh in the June quarter to Rs 85.91 lakh in the September quarter. Total expenses increased by Rs 2.56 crore, from Rs 16.05 crore to Rs 18.61 crore, which was below the Rs 3.06 crore increase in total income between the two quarters.

Basic earnings per share increased to Rs 0.81 in the September quarter from Rs 0.37 in the June quarter. The reported paid-up equity share capital was Rs 9.66 crore in both quarterly columns. The statement presents the September 2026 quarter alongside the June 2026 quarter and the corresponding half-year periods.

What do the first-half results show for Sandu Pharmaceuticals?

Sandu Pharmaceuticals reported revenue from operations of Rs 35.82 crore for the six months ended September 30, 2026. Other income was Rs 10.44 lakh, bringing first-half total income to Rs 35.92 crore. The six-month revenue consists of Rs 16.39 crore in the June quarter and Rs 19.43 crore in the September quarter.

Profit before exceptional items and tax was Rs 1.22 crore for the six months ended September 30, 2026, compared with Rs 1.05 crore for the six months ended September 30, 2025. The difference was Rs 16.65 lakh. Basic earnings per share for the latest half year were Rs 1.08, versus Rs 1.05 in the corresponding prior-year half year.

First-half total expenses were Rs 34.70 crore, against total income of Rs 35.92 crore. The September quarter supplied more than half of the Rs 35.82 crore first-half revenue from operations, at Rs 19.43 crore, while the June quarter contributed Rs 16.39 crore. The filing does not provide separate half-year revenue by product category or geography.

What changed in Sandu Pharmaceuticals' balance sheet?

Sandu Pharmaceuticals reported total assets of Rs 57.18 crore as of September 30, 2026, compared with Rs 55.87 crore at March 31, 2026. Total equity increased to Rs 44.01 crore from Rs 43.67 crore over that period. Equity share capital remained Rs 9.66 crore at both reporting dates, while other equity was Rs 34.35 crore at September 30.

Inventories increased to Rs 11.33 crore at September 30 from Rs 10.47 crore at March 31. Trade receivables rose to Rs 7.83 crore from Rs 5.41 crore, while cash and cash equivalents declined to Rs 3.14 crore from Rs 5.91 crore. Bank balances other than cash and cash equivalents were Rs 83.72 lakh at September 30, compared with Rs 94.82 lakh at the March year-end.

Current liabilities were Rs 11.44 crore at September 30, 2026, compared with Rs 10.42 crore at March 31, 2026. Trade payables to parties other than micro and small enterprises rose to Rs 4.78 crore from Rs 3.85 crore. Other current liabilities declined to Rs 1.32 crore from Rs 2.07 crore, while finance lease obligations classified as current liabilities were Rs 6.43 lakh.

The cash-flow statement says it was prepared using the indirect method under Ind AS 7, Statement of Cash Flows. Its reconciliation identifies cash and cash equivalents of Rs 3.14 crore at September 30, 2026 and Rs 5.91 crore at March 31, 2026, matching the balance-sheet figures shown for those dates.

Which business segment does Sandu Pharmaceuticals report?

Sandu Pharmaceuticals reports one business segment, Ayurvedic Proprietary Medicines. Management said it evaluates the company using revenue and operating income in this single segment, so no separate segment information was disclosed under Ind AS 108.

The single-segment presentation means that September-quarter revenue of Rs 19.43 crore and first-half revenue of Rs 35.82 crore are reported for the company as a whole. The filing does not split either figure among products, customer groups or geographic markets. It also says prior-period figures were reclassified or regrouped where necessary.

The board meeting that approved the September 2026 results began at 4.00 p.m. and concluded at 6.40 p.m. on November 14, 2026. Sandu Pharmaceuticals stated that the results were published in accordance with Regulation 33 of the Securities and Exchange Board of India listing regulations, while the financial statements followed Ind AS requirements under the Companies Act, 2013.

Conclusion

Sandu Pharmaceuticals recorded a sequential increase in September-quarter revenue from Rs 16.39 crore to Rs 19.43 crore, while profit before exceptional items and tax increased from Rs 36.05 lakh to Rs 85.91 lakh. For the six months ended September 30, 2026, revenue from operations was Rs 35.82 crore and profit before exceptional items and tax was Rs 1.22 crore, compared with Rs 1.05 crore in the corresponding prior-year period.

The next disclosures will clarify how the balance-sheet movements at September 30 develop, particularly trade receivables of Rs 7.83 crore, inventories of Rs 11.33 crore and cash and cash equivalents of Rs 3.14 crore. Sandu Pharmaceuticals has disclosed no product-level segment split because management evaluates its Ayurvedic Proprietary Medicines business as one segment.